Placebo Challenge for Statin Intolerance?

ACC Conference Reporter

ACC.16 | CHICAGO — The GAUSS-3 trial again demonstrated PCSK9 inhibitor superiority to other options for cutting cholesterol in truly statin-intolerant people, but perhaps its greater contribution was that a blinded placebo challenge indicated that intolerable muscle symptoms reported with multiple statins actually didn't stem from the statin for about 60% of patients. Read More >>>

Keywords: ACC Annual Scientific Session

< Back to Listings